Display options
Cite
Guo X, Zhang Y, Liu L, et al. HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells. Onco Targets Ther. 2020;13:1507-1518doi: 10.2147/OTT.S231249.
Guo, X., Zhang, Y., Liu, L., Yang, W., & Zhang, Q. (2020). HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells. OncoTargets and therapy, 131507-1518. https://doi.org/10.2147/OTT.S231249
Guo, Xiong, et al. "HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells." OncoTargets and therapy vol. 13 (2020): 1507-1518. doi: https://doi.org/10.2147/OTT.S231249
Guo X, Zhang Y, Liu L, Yang W, Zhang Q. HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells. Onco Targets Ther. 2020 Feb 18;13:1507-1518. doi: 10.2147/OTT.S231249. eCollection 2020. PMID: 32110048; PMCID: PMC7035897.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2020 Feb 18;13:1507-1518. doi: 10.2147/OTT.S231249. eCollection 2020.

HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells.

OncoTargets and therapy

Xiong Guo, Yang Zhang, Ling Liu, Weiming Yang, Qi Zhang

Affiliations

  1. Colorectal and Anal Surgical Department, Xiangya Hospital Central South University, Changsha 410008, People's Republic of China.
  2. Hepatobiliary and Enteric Surgery Research Center, Xiangya Hospital Central South University, Changsha 410008, People's Republic of China.
  3. Department of Hepatobiliary and Pancreatic Surgery, Xiangya Hospital Central South University, Changsha 410008, People's Republic of China.

PMID: 32110048 PMCID: PMC7035897 DOI: 10.2147/OTT.S231249

Abstract

BACKGROUND: Accumulating evidence determined that lncRNAs play multiple roles in cell progression in colorectal cancer (CRC). Long noncoding RNA (lncRNA) hepatocyte nuclear factor 1 homeobox A (HNF1A)-antisense RNA 1 (AS1) has been identified to affect cell growth and disease diagnosis in various cancers, including CRC. However, the underlying regulatory mechanism of HNF1A-AS1 in cell progression and glycolysis has not been fully explored in CRC.

MATERIALS AND METHODS: The expression of HNF1A-AS1, microRNA-124 (miR-124) and Myosins of class VI (MYO6) was detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The analysis of glucose consumption, lactate production and hexokinase 2 (HK2) protein level was used to assess glycolysis in cells. The protein level of HK2 and MYO6 was measured with Western blot. Cell migration and invasion were evaluated using the transwell assay. The relationship among HNF1A-AS1, miR-124 and MYO6 was determined via luciferase reporter and RNA immunoprecipitation (RIP) assay.

RESULTS: In this study, we found that HNF1A-AS1 was upregulated in CRC tissues and cell lines. Functional experiments determined that reduction of HNF1A-AS1 or promotion of miR-124 inhibited cell migration and invasion as well as glycolysis in CRC cells. What' more, luciferase reporter assay manifested that miR-124 was a target of HNF1A-AS1 and MYO6 was a target mRNA of miR-124 in CRC cells. Additionally, reverse experiments showed that the effects of si-HNF1A-AS1 on colorectal cancer cells were impaired by anti-miR-124 and the effects of high miR-124 expression on CRC cells were rescued by upregulating MYO6. HNF1A-AS1 regulated MYO6 expression via targeting miR-124 in CRC cells.

CONCLUSION: In this study, we first found that HNF1A-AS1 regulated cell migration, invasion and glycolysis via modulating miR-124/MYO6 in CRC cells.

© 2020 Guo et al.

Keywords: HNF1A-AS1; MYO6; colorectal cancer; miR-124

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Biol Proced Online. 2014 Sep 15;16:11 - PubMed
  2. Gut. 2014 Jun;63(6):881-90 - PubMed
  3. Cancer Biother Radiopharm. 2015 Oct;30(8):330-5 - PubMed
  4. Cancer Discov. 2013 Oct;3(10):1105-7 - PubMed
  5. BMC Med. 2008 Jun 24;6:14 - PubMed
  6. Biochem Biophys Res Commun. 2016 Oct 7;479(1):28-32 - PubMed
  7. Biomed Pharmacother. 2018 Feb;98:433-439 - PubMed
  8. Mol Cancer. 2016 Sep 29;15(1):62 - PubMed
  9. Cell Biosci. 2017 Apr 21;7:19 - PubMed
  10. Cancer Med. 2018 May 29;: - PubMed
  11. Biomed Pharmacother. 2018 Apr;100:101-107 - PubMed
  12. Biochim Biophys Acta. 2014 Nov;1839(11):1097-109 - PubMed
  13. Hum Cell. 2018 Jan;31(1):14-21 - PubMed
  14. Mol Cancer. 2018 Feb 21;17(1):63 - PubMed
  15. Tumour Biol. 2016 May;37(5):5657-61 - PubMed
  16. Mol Cancer. 2017 Jul 24;16(1):129 - PubMed
  17. World J Clin Oncol. 2014 May 10;5(2):134-41 - PubMed
  18. Cancer Biomark. 2017 Dec 6;20(4):417-424 - PubMed
  19. Jpn J Clin Oncol. 2010 Apr;40(4):281-5 - PubMed
  20. Oncol Lett. 2018 Apr;15(4):4535-4540 - PubMed
  21. Gene. 2016 Nov 15;593(1):100-109 - PubMed
  22. Cancer Cell Int. 2016 Feb 16;16:9 - PubMed
  23. Mol Cancer. 2018 Aug 11;17(1):118 - PubMed
  24. Oncol Rep. 2016 Sep;36(3):1285-92 - PubMed
  25. Apoptosis. 2017 Dec;22(12):1543-1552 - PubMed
  26. J Exp Med. 2011 Feb 14;208(2):313-26 - PubMed
  27. Mol Cancer. 2018 May 2;17(1):87 - PubMed
  28. World J Surg Oncol. 2017 Aug 10;15(1):153 - PubMed
  29. Am J Transl Res. 2016 Aug 15;8(8):3503-12 - PubMed
  30. Cancer Sci. 2014 Aug;105(8):951-5 - PubMed
  31. Cell Physiol Biochem. 2018;51(1):113-128 - PubMed
  32. Cell Physiol Biochem. 2016;38(5):1785-95 - PubMed
  33. J Cell Physiol. 2018 Sep;233(9):6750-6757 - PubMed
  34. Cell Mol Life Sci. 2013 Dec;70(24):4785-94 - PubMed
  35. J Cell Sci. 2001 Aug;114(Pt 15):2713-22 - PubMed
  36. Oncotarget. 2015 Apr 20;6(11):9160-72 - PubMed
  37. Maturitas. 2015 Mar;80(3):258-64 - PubMed
  38. Onco Targets Ther. 2018 Aug 31;11:5325-5332 - PubMed
  39. Cancer Res. 1986 Jan;46(1):1-7 - PubMed
  40. Cancer Metab. 2013 Jan 23;1(1):2 - PubMed
  41. Cancer Lett. 2015 Jul 10;363(1):17-27 - PubMed
  42. Acta Biochim Biophys Sin (Shanghai). 2016 May;48(5):430-6 - PubMed
  43. Int J Oncol. 2018 Aug;53(2):551-566 - PubMed
  44. IUBMB Life. 2018 Apr;70(4):276-290 - PubMed
  45. Biomed Pharmacother. 2018 Feb;98:594-599 - PubMed
  46. Biol Res. 2017 Oct 2;50(1):32 - PubMed
  47. Mol Cancer. 2017 Jan 13;16(1):9 - PubMed
  48. Mol Med Rep. 2017 Oct;16(4):4694-4700 - PubMed
  49. Biochim Biophys Acta. 2016 Sep;1862(9):1685-95 - PubMed
  50. Mol Cell. 2013 Sep 26;51(6):792-806 - PubMed

Publication Types